N/A
Completed N=297
Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test
Source: ClinicalTrials.gov NCT04904510 ↗Enrolled (actual)
297
Serious AEs
0.0%
Results posted
Feb 2023
Primary outcomePrimary: Test Concordance — 85.3 positive percent agreement
Summary
The INDICAID™ Rapid Antigen Test was used in real-world outbreak testing. The antigen test was used together with PCR testing. This study was designed to evaluate whether the addition of a rapid antigen test decreased time to results in a real-world setting.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Test Concordance |
85.3 | — |
Eligibility Criteria
Inclusion Criteria
- at least 5 years of age and report onset
- at least two of the following COVID-19 symptoms within 5 days or less: fever or chills, fatigue, sore throat, congestion or runny nose, cough, headache, diarrhea, shortness of breath or difficulty breathing, muscle or body aches, new loss of taste or smell, nausea, or vomiting.
Exclusion Criteria
- That do not fit inclusion criteria or vulnerable populations
Data sourced from ClinicalTrials.gov (NCT04904510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.